Preclinical pharmacokinetics of radiolabelled hyaluronan

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F12%3A10124217" target="_blank" >RIV/00216208:11160/12:10124217 - isvavai.cz</a>

Výsledek na webu

<a href="http://rabbit.if-pan.krakow.pl/pjp/pdf/2012/2_428.pdf" target="_blank" >http://rabbit.if-pan.krakow.pl/pjp/pdf/2012/2_428.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Preclinical pharmacokinetics of radiolabelled hyaluronan

Popis výsledku v původním jazyce

Background: Hyaluronan (HYA) is a high molecular weight glucosaminoglycan with a great perspective for medical applications. Because HYA is widespread in the body, it is difficult to determine the fate of exogenously administered HYA. Methods: In this study, HYA of different molecular weights (0.1-1 MDa) was labelled with Tc-99m, and the distribution profiles were determined after administrating the HYA to rats. Results: After the intravenous administration of Tc-99m-HYA, a rapid decrease in the radioactivity of blood samples was observed, presumably because of Tc-99m-HYA uptake by the liver; only minimal signs of liver radioactivity washout were detected. After the oral administration of Tc-99m-HYA, no significant absorption to the central compartmentwas found. A preliminary study using C-14-HYA exhibited a different distribution profile than Tc-99m-HYA because of the different administered dose and the fate of the degradation products. Even with C-14-HYA, only traces of radioactivit

Název v anglickém jazyce

Preclinical pharmacokinetics of radiolabelled hyaluronan

Popis výsledku anglicky

Background: Hyaluronan (HYA) is a high molecular weight glucosaminoglycan with a great perspective for medical applications. Because HYA is widespread in the body, it is difficult to determine the fate of exogenously administered HYA. Methods: In this study, HYA of different molecular weights (0.1-1 MDa) was labelled with Tc-99m, and the distribution profiles were determined after administrating the HYA to rats. Results: After the intravenous administration of Tc-99m-HYA, a rapid decrease in the radioactivity of blood samples was observed, presumably because of Tc-99m-HYA uptake by the liver; only minimal signs of liver radioactivity washout were detected. After the oral administration of Tc-99m-HYA, no significant absorption to the central compartmentwas found. A preliminary study using C-14-HYA exhibited a different distribution profile than Tc-99m-HYA because of the different administered dose and the fate of the degradation products. Even with C-14-HYA, only traces of radioactivit

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmacological Reports

ISSN

1734-1140

e-ISSN

—

Svazek periodika

64

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

10

Strana od-do

428-437

Kód UT WoS článku

000305546700023

EID výsledku v databázi Scopus

—